Objective: To compare response rates among patients with major depressive disorder (MDD) treated with either moclobemide, an antidepressant thought to simultaneously enhance both noradrenergic and serotonergic neurotransmission, or selective serotonin reuptake inhibitors (SSRIs).
T he serendipitous discovery of the precursors of 2 of the major contemporary antidepressant families during the late 1950s-iproniazid for the monoamine oxidase inhibitors and imipramine for the tricyclic antidepressants-has led to the subsequent development of numerous antidepressant compounds (1) . Unfortunately, many depression patients continue to remain symptomatic despite several treatments (2, 3) . Until recently, known differences among available antidepressants were generally limited to aspects of safety and tolerability (1) . However, over the past few years, several studies have suggested that treatment with antidepressants simultaneously enhancing noradrenergic and serotonergic neurotransmission, including venlafaxine (4), duloxetine (5) , and the tricyclic antidepressant clomipramine (6, 7) , may result in higher response or remission rates than treatment with antidepressants that selectively enhance serotonergic neurotransmission.
Similar to clomipramine, venlafaxine, and duloxetine, the antidepressant moclobemide also simultaneously enhances serotonergic and noradrenergic neurotransmission (1) . Specifically, moclobemide is a selective and reversible inhibitor of the monoamine oxidase-A isoenzyme (1) and is approved for the treatment of depression in Europe, Canada, and Australia. Although an earlier metaanalysis of 7 published RCTs found no difference in response rates between MDD patients treated with moclobemide or an SSRI (8) , several double-blind RCTs comparing moclobemide with an SSRI for MDD treatment have been published since then, involving a total of 513 patients (9) (10) (11) (12) (13) . Since the statistical power of a metaanalysis to detect differences in efficacy between 2 treatments is directly related to the number and sample size of the individual RCTs pooled, and in light of the significant increase in the number of double-blind RCTs comparing moclobemide with an SSRI for the treatment of MDD, it is important to reexamine whether there are any differences in efficacy or tolerability between these 2 treatments. Therefore, we conducted a systematic review and metaanalysis of all randomized, double-blind antidepressant trials published to date that compared moclobemide with an SSRI for the treatment of MDD.
Materials and Methods

Data Sources and Search Strategy
Studies were first identified from searches of PubMed-MEDLINE. We conducted searches by crossreferencing the word moclobemide with each of the following words: fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram. We used the limits function in PubMed to limit our searches to articles that described RCTs. No limits on language or year of publication were used. We then repeated these searches, using EMBASE and the Cochrane databases.
Study Selection. We selected for double-blind RCTs comparing moclobemide with at least one SSRI for the acute-phase treatment of MDD. We then selected for studies that also used either the HDRS (14) or the MADRS (15) as their primary outcome measure and reported response rates, defined as a 50% or greater decrease in depression severity (according to the HDRS or MADRS) from baseline to endpoint.
Reports that focused exclusively on the treatment of patients with bipolar disorder, dysthymic disorder, minor depressive disorder, or seasonal affective disorder, as well as reports containing patients with psychotic features or patients with active alcohol or substance abuse disorders, were excluded from the analysis. We also excluded reports containing previously published data. We each conducted the search separately and then compared our results. It was agreed that any discrepancy in studies selected for inclusion or exclusion would be resolved by a third colleague not involved in the metaanalysis.
Data Extraction. Using a precoded form, we extracted the following data from studies meeting inclusion criteria for the metaanalysis: the criteria used to establish the diagnosis of MDD, the number of patients randomized to each treatment arm, the antidepressants and dosages used, the duration of the trial, the primary outcome measure used (HDRS or MADRS), the response rates, the overall discontinuation rates, the rate of discontinuation due to adverse events, the rate of discontinuation due to inefficacy, and the rates of 5 adverse events (nausea, fatigue or somnolence, insomnia, anxiety, and headaches). In studies that reported the response rates, discontinuation rates, or adverse event rates graphically rather than numerically, we extracted the rates for treatment groups by measuring each data point as performed in a recent, large metaanalysis of antidepressant clinical trials (16) . 
Quantitative Data Synthesis
The primary outcome of the metaanalysis was to compare response rates between the moclobemide and SSRI treatment groups. To accomplish this, we pooled the estimates of response rates among studies after examining for homogeneity by using the test statistic proposed by DerSimonian and Laird (17) . We analyzed the pooled results, using randomeffects models to ascertain differences in pooled estimates according to the 2 techniques (17-19). We then examined for publication bias, using a funnel plot and Eggers test statistic (20) .
Secondary outcomes included comparing overall discontinuation rates, the rate of discontinuation due to adverse events, the rate of discontinuation due to inefficacy, and rates for 5 adverse events (nausea, fatigue or somnolence, insomnia, anxiety, and headaches). We also used a random-effects model to compare the moclobemide and SSRI treatment groups on all secondary outcome measures. Finally, we conducted a metaregression to examine the impact of mean moclobemide dosage on the study response rate RR. All analyses were performed with the metapackage of metaanalytic tools as implemented in Stata 8.0.
Results
Initially, we identified 30 abstracts through PubMed. Of these, 14 were excluded for various reasons (such as focusing on other topics or being reviews). The remaining 16 abstracts described double-blind RCTs comparing moclobemide with an SSRI for MDD treatment, so we obtained the complete articles and reviewed them thoroughly. We identified 12 articles describing studies that met our inclusion criteria for the metaanalysis (Table 1) ; none of these articles met any of the exclusion criteria. The remaining 4 studies contained data that had previously been published in 1 of the 12 studies identified for inclusion in the metaanalysis (21-24) (see Figure 1 for details). The 12 studies we pooled involved a total of 1207 outpatients with MDD randomized to treatment with either moclobemide or one of fluoxetine (10, 11, (25) (26) (27) (28) (29) , fluvoxamine (30, 31) , sertraline (9,12), or paroxetine (13) . None of these 12 studies involved the use of placebo. All 12 studies reported overall discontinuation rates: 11 reported discontinuation rates due to adverse events, 10 reported discontinuation rates due to lack of efficacy, 9 reported rates of nausea, 9 reported rates of headaches, 6 reported rates of fatigue or somnolence, and 6 reported rates of anxiety. All 12 studies were sponsored by Roche, the maker of moclobemide.
No additional studies were identified by EMBASE or the Cochrane databases. There was no discrepancy between the 2 investigators' choices regarding study selection.
Analysis of Primary and Secondary Outcome Measures
We found no statistically significant difference in response rates between the moclobemide and SSRI treatment groups. Specifically, across the trials, the pooled RR for response rates was 1.08 (95%CI, 0.92 to 1.26; P = 0.314) for the randomeffects model (Figure 2 ). Simply pooling response rates for the 2 agents resulted in a 62.1% response rate for moclobemide and a 57.5% response rate for the SSRIs ( Figure  3) . A test for heterogeneity suggested no significant heterogeneity among the included studies (Q = 4.361, df 11; P = 0.958). The Eggers test was not suggestive for the presence of Williams and others (25) Geertz and others (26) Lonnqvist and others (27) Gattaz and others (28) Orsel Donbak and others (9) Raynaert and others (29) Duarte and others (10) Lapierre and others (11) Soggard and others (12) Pini and others (13) Combined publication bias (P = 0.643), nor was visual inspection of the funnel plot ( Figure 4 ). We also observed no between-group differences in overall discontinuation rates (RR 0.9; 95%CI, 0.6 to 1.1; P = 0.463), in discontinuation rates due to adverse events (RR 0.6; 95%CI, 0.3 to 1.3; P = 0.247), in discontinuation rates due to lack of efficacy (RR 1.2; 95%CI, 0.6 to 2.4; P = 0.578), in rates of fatigue and somnolence (RR 0.6; 95%CI, 0.3 to 1.1; P = 0.127), or in rates of insomnia (RR 1.0; 95%CI, 0.7 to 1.4; P = 0.928). SSRI treatment was associated with higher rates of nausea (RR 0.6; 95%CI, 0.5 to 0.8; P = 0.001), headaches (RR 0.6; 95%CI, 0.5 to 0.8; P = 0.001), and treatment-emergent anxiety (RR 0.5; 95%CI, 0.2 to 0.9; P = 0.029), compared with treatment with moclobemide. Finally, we saw no statistically significant relation between the mean moclobemide dosage and the RR of response rates (P = 0.646).
Discussion
In this metaanalysis, we found no evidence suggesting a difference in response rates between the antidepressant moclobemide, a monoamine oxidase-A selective inhibitor, and SSRIs for the treatment of MDD. Specifically, the likelihood of patients experiencing significant clinical improvement during treatment, defined as a 50% or greater reduction in depressive symptom severity, was comparable for both agents. Simply pooling response rates between the 2 agents resulted in a 62.1% response rate for moclobemide and a 57.5% response rate for the SSRIs. These findings are not consistent with other reports suggesting that the treatment of MDD with antidepressant agents combining a serotonergic and noradrenergic mechanism of action is associated with greater response and remission rates than is treatment with an SSRI (4-7). In addition, we did not find that the mean moclobemide dosage for each study significantly influenced the relative risk of responding to moclobemide, compared with the SSRIs. Further, similar proportions of moclobemideand SSRI-treated patients discontinued treatment for any reason, or specifically because of lack of clinical improvement or side effects. We also observed similar rates of fatigue or somnolence and insomnia in the 2 treatment groups. However, SSRI treatment was associated with higher rates of nausea, headaches, and treatment-emergent anxiety than was treatment with moclobemide.
We note several important limitations of our work. First, the analysis involved pooling studies comparing moclobemide with fluvoxamine, fluoxetine, sertraline, paroxetine, and to a much lesser extent, paroxetine. Since studies involving citalopram and escitalopram were not included, conclusions drawn from this study cannot be generalized to all SSRIs. In light of this limitation, it is important to point out that, although previous research does not suggest any difference in overall efficacy between citalopram and the other SSRIs relates to the fact that none of the included studies had a placebo comparison group. Therefore, we cannot draw any conclusions about the assay sensitivity of these trials, whose response rates may have been confounded by robust, nonspecific, placebo-like effects. An additional limitation is that our metaanalysis involved pooling clinical trials with numerous inclusion and exclusion criteria. Hence, it may not be possible to directly extend the findings of this study to groups of patients typically excluded from participating in RCTs. In addition, since these trials included fairly heterogeneous populations, our analysis cannot rule out the possibility of significant differences in response rates in specific subgroups, such as patients with MDD and atypical features. Further, pooled analyses and metaanalyses involve combining studies of heterogeneous design. In general, a single clinical trial of equivalent statistical power can yield more accurate estimates of a treatment effect. One potential source of heterogeneity, for instance, involves whether the MADRS or HDRS scales were used to determine clinical improvement, although both scales appear to be highly correlated and equally sensitive to change (39) (40) (41) . However, for the most part, the trials pooled in this analysis shared many similarities, including a 1-week washout period prior to randomization, a comparable baseline depression severity threshold for inclusion, and similar treatment duration. Finally, other limitations specifically pertain to the identification of studies to be included in pooled analyses or metaanalyses, including the phenomenon of publication bias. Thus, although we included all published studies to date, it is quite possible that studies sponsored by Roche or other sources have been conducted but not yet published. Nevetheless, our analysis provided no statistical evidence suggesting the presence of publication bias. Conclusions : Ces résultats suggèrent que le moclobémide et les ISRS diffèrent en ce qui concerne le profil des effets secondaires, mais pas dans leur efficacité générale à traiter le TDM.
